ROCKVILLE, Md.--(BUSINESS WIRE)--Precision Biologics is pleased to announce the addition of Dana-Farber/Harvard Cancer Center (DF/HCC) and Massachusetts General Hospital (MGH) as collaborators on its ongoing Phase 2 clinical trial with its lead therapeutic compound NPC-1C (NEO-102). Thomas Jefferson University |Sidney Kimmel Cancer Center and the California Pacific Medical Center Research Institute have also joined to accrue patients to this study.
Help employers find you! Check out all the jobs and post your resume.
